Physician profile
Michael S Dew
NPI 1093701427
$26,617.62
in general payments reported to CMS, 2019-2025
74 companies · $4,366 in 2025
The $4,366 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,457 · 2020: $3,262 · 2021: $3,757 · 2022: $3,508 · 2023: $4,126 · 2024: $4,142 · 2025: $4,366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $25.23 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,591.24 |
| Education | $25.23 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,817.06 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Abbvie INC. | $1,736.18 | 2019-2025 | Ubrelvy, Duopa, Botox |
| Novartis Pharmaceuticals Corporation | $1,524.58 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $1,277.34 | 2019-2025 | Ultomiris, Soliris |
| Biogen, INC. | $1,248.27 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Mdd US Operations, LLC | $1,078.26 | 2019-2025 | Gocovri, Apokyn, Xadago |
| Neurelis, INC. | $1,033.78 | 2020-2025 | Valtoco |
| Lundbeck LLC | $925.63 | 2019-2025 | Vyepti, Rexulti |
| Teva Pharmaceuticals USA, INC. | $846.44 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $746.05 | 2019-2025 | Ingrezza, Ongentys |
| Eisai INC. | $739.91 | 2019-2025 | |
| Lilly USA, LLC | $728.64 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Genzyme Corporation | $566.74 | 2019-2025 | |
| Genentech USA, INC. | $551.46 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Acadia Pharmaceuticals INC | $548.88 | 2019-2025 | Nuplazid, Daybue |
Show all 74 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.